Kidney Disease

SHARP, Study of Heart and Renal Protection

Sponsored by: University of Oxford, UK
Funded by: Merck Schering Plough

SHARP is an international, double-blinded, placebo-controlled, randomized trial sponsored by the University of Oxford, UK. The Berman Center is the US Regional Coordinating Center (RCC). The Berman Center is also a SHARP clinical site, enrolling participants locally.

SHARP will enroll approximately 9,000 patients with Chronic Kidney Disease (CKD) without coronary heart disease (CHD). Its purpose is to assess the effect of a cholesterol-lowering therapy for the reduction of cardiovascular (CV) events (non-fatal myocardial infarction or cardiac death, non-fatal or fatal stroke, or revascularization). Of the 9,000 participants, 3,000 are expected to be on dialysis and 6,000 pre-dailysis. The active treatment is a combination of simvastatin (20mg daily) and ezetimibe (10mg daily).